{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260401820161/en/PureTech-Founded-Entity-Seaport-Therapeutics-Announces-Positive-Proof-of-Concept-Topline-Results-from-Ongoing-Phase-1-Trial-of-GlyphAgo%E2%84%A2-in-Healthy-Volunteers", "message": "News view counter 641988 successfully enlarged"}